Raloxifene/Evista: The only serm with medical indiication for proven bone building

Raloxifene, trade name Evista, is the only drug approved by the FDA for bone building that is also a member of the SERM group of anti-estrogen drugs. Unlike Tamoxifen/Nolvadex, Raloxifene does not interfere with the plasma level of aromatase inhibitors such as Femara (Letrozole) and Arimidex (anastrozole).

In studies, concurrent use of Tamoxifen with either aromatase inhibitor Letrozole or Anastrozole decreased the plasma level of each drug anywhere between 27% on the low end, all the way up to 40%! This is significant considering the cost and effectiveness of these aromatase inhibitors. You can ruin up to 40% of the dose of your Femara by taking Nolvadex with it?! Yes, you can!!

This interesting fact makes Raloxifene all that much more interesting. Raloxifene has a significant effect on limiting fractures in both men and women (post-menopausal). It has been shown to aid in bone density of the vertebral column as well as the hip/pelvis.

Raloxifene is a benzothiophene derivative, not a triphenylethylene structure like Clomid and Nolvadex. It also has an equal binding affinity to estradiol which means that it will be effective in the male breast for treatment and or prevention of gynecomastia.

Raloxifene comes in 60mg tablets and has an overall effect on cholesterol of decreasing it, while the HDL often remains unchanged. This would shift the HDL:LDL ratio up, in favor of less cardiovascular risk. Although this is the physiology behind the health benefit of Raloxifene, there are not conclusive studies showing that this small shift is significant with respect to cardiovascular risk.

Raloxifene has a half-life of just over a day, and an extremely low rate of bioavailability (2%), so it is important not to miss your daily dose if you are using this drug for estrogen/gyno protection. If you are in an acute phase of gyno flare-up, you definitely cannot afford to miss a dose.